Medical Oncologist
Pancreatic cancer treatment
Targeted Therapy for Pancreatic Cancer: — What Testing Can Reveal
Targeted therapy is an option for a minority of people with pancreatic cancer — those whose tumour carries a specific actionable mutation. Testing is the only way to know whether that applies to you, and it should happen before treatment decisions are made.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Most do not qualify — The large majority of pancreatic tumours carry mutations that do not yet have an approved targeted drug.
- Testing decides it — Biomarker testing on your tumour tissue and a blood test for BRCA determine whether a targeted option exists.
- BRCA is the clearest route — An inherited BRCA mutation is the most established basis for targeted therapy in this cancer.
- Evidence is still emerging — Several targets are under active study — your oncologist can tell you whether a trial might apply.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy is available for a minority of pancreatic cancer patients — those whose tumours carry a specific actionable mutation. NCCN and ASCO recommend comprehensive biomarker testing for all eligible patients, because the mutation, not the diagnosis alone, determines whether a targeted drug is an option.
Which mutations are tested before treating pancreatic cancer?
The main mutations tested are BRCA1 and BRCA2 (both inherited and acquired), microsatellite instability high (MSI-H), mismatch-repair deficiency, KRAS G12C specifically, and NTRK gene fusions. NCCN guidance recommends this panel for all patients with advanced disease before treatment decisions are made.
Tumour tissue from your biopsy is used for most of these tests. Germline BRCA testing uses a blood sample, separate from the tissue test — ask your team to confirm both have been ordered.
Results typically take one to two weeks. If the original biopsy sample is too small, a repeat procedure may be needed before the question can be fully answered.
Which targeted drugs are approved for pancreatic cancer?
Olaparib, a PARP inhibitor, is approved for maintenance treatment in patients with a germline BRCA1 or BRCA2 mutation whose metastatic disease has not progressed on platinum-based chemotherapy. This is the most established targeted therapy pathway for this cancer, recognised in NCCN and ESMO guidance.
For tumours that test MSI-H or mismatch-repair deficient, pembrolizumab is approved regardless of cancer type — pancreatic cancer included. NTRK fusion-positive tumours, which are uncommon in this cancer, may be eligible for larotrectinib or entrectinib under tumour-agnostic approvals.
Agents targeting the KRAS G12C variant are being evaluated in clinical trials and have shown early activity. Ask your oncologist which specific KRAS variant your tumour carries, because different variants do not respond to the same agents.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Why do most people with pancreatic cancer not qualify for targeted therapy?
Most patients do not qualify because their tumour carries a KRAS variant — G12D, G12V, and others — for which no approved targeted drug currently exists. KRAS mutations are extremely common in this cancer, but drugs that match most of those variants are still in active research.
The one exception is KRAS G12C, a less common variant that some investigational agents can target. NCCN and ASCO describe this as an area of ongoing investigation, not yet established practice.
Being told you do not have an actionable mutation is not a statement about your prognosis. It means chemotherapy, which has several active regimens for this cancer, is the treatment most likely to help you right now.
What should I ask my oncologist about targeted therapy?
- Has biomarker testing been done on my tumour tissue?
- Have I been tested for germline BRCA1 and BRCA2?
- Does my tumour show MSI-H or mismatch-repair deficiency?
- Is there a KRAS mutation — and if so, which variant exactly?
- Are there clinical trials open for my mutation profile?
- If I am not eligible now, should testing be repeated later?
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does pancreatic cancer respond to targeted therapy?
A minority of patients respond — specifically those whose tumour carries an actionable mutation. The most established example is germline BRCA1 or BRCA2 mutation, where olaparib is approved as maintenance therapy after platinum-based chemotherapy. MSI-H tumours and NTRK fusions also have approved options. For most patients, no actionable mutation is present, and chemotherapy remains the primary systemic treatment. Biomarker testing is the only way to establish which group you are in.
What is a BRCA mutation and why does it matter in pancreatic cancer?
BRCA1 and BRCA2 are DNA-repair genes — when either is faulty, PARP inhibitors can exploit that weakness in cancer cells, making them an approved treatment option. In pancreatic cancer specifically, this is the most established targeted therapy route. Germline BRCA mutations are more common in people with a family history of breast, ovarian, or pancreatic cancer. Testing uses a blood sample and is separate from the tumour tissue test. If germline testing has not been done, ask your oncologist to arrange it.
My tumour has a KRAS mutation — does that mean I can have targeted therapy?
Not automatically. KRAS mutations are very common in pancreatic cancer, but most are variants — G12D, G12V, and others — for which no approved targeted drug exists. The exception is KRAS G12C, a less common variant that investigational agents can target, with trials actively enrolling. Ask your oncologist which specific variant your tumour carries. If it is G12C, a trial may be relevant. If it is another variant, targeted therapy is not available outside of research settings at this time.
What does MSI-H mean and how does it affect my options?
MSI-H — microsatellite instability high — means your tumour's DNA mismatch-repair system is deficient, and that makes an approved immunotherapy drug available regardless of cancer type. Pembrolizumab is approved for any MSI-H solid tumour, including pancreatic cancer. MSI-H is uncommon in this cancer, but when it is present there is a clear approved option attached to it — which is why testing for it is one of the first steps in biomarker assessment.
Is targeted therapy available at CION?
Targeted therapy is administered as day care at CION centres, which means most people do not need an overnight stay. Where biomarker testing or response-assessment imaging such as PET-CT is needed, these are coordinated with partner laboratories and imaging centres. CION does not provide CAR-T or cell therapy. If your mutation profile points toward a treatment that requires a specialist programme, your team will discuss a referral.
I was not eligible before — should I be retested if my disease changes?
Yes, it is worth asking. Tumours can change their characteristics over time, so a test done at first diagnosis may not describe the disease you have now. Clinical trials for KRAS variants and other targets also open regularly — an option that did not exist a year ago may now be available. If your disease has progressed or a new biopsy has been taken, ask your oncologist whether biomarker testing should be repeated on the most recent sample.